Common Contracts
1 similar null contracts
Agreement Includes a Joint Development Committee and Eddingpharm’s Participation in Global Registration TrialsAugust 28th, 2013
WALTHAM, Mass., Sept. 4, 2013—Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, a leading specialty pharmaceutical company in China, entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market and sell entinostat in China and certain other Asian countries/regions. Financial details are undisclosed but include milestone payments and royalties on future entinostat sales. Details of the agreement include:
